Sign in
Explore the registryTrack Ramucirumab's trials

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

RamucirumabOngoingRecruitingPhase 1Open NCT06445972 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…